Skip to content

Train with us

Explore

StudentsStudent union partnership: your class fund
Sign upLog in

Rheumatoid arthritis (RA)

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterised by inflammatory synovitis affecting the small joints of the hands, wrists…

Posted by

Anthony BAILLON

Physiotherapist

Rheumatology · Physiotherapy · Autoimmune diseases

In brief

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterised by inflammatory synovitis affecting the small joints of the hands, wrists and feet symmetrically, and capable of leading to irreversible joint destruction through an invasive pannus. It presents with inflammatory pain, synovial swelling and prolonged morning stiffness. Diagnosis combines clinical findings, laboratory tests (rheumatoid factor, anti-CCP antibodies with a specificity above 95 %) and imaging, following the 2010 ACR/EULAR criteria. Management follows the Treat-to-Target strategy aiming for remission, with methotrexate as first line, completed by therapeutic exercise. It affected 17.6 million people worldwide in 2020, with a female predominance (×2.5).

Clinical summary based on the EULAR 2022 and ACR 2021 recommendations and on 2023-2025 meta-analyses covering epidemiology, diagnosis, Treat-to-Target and non-pharmacological management.

Diagnosis Treat-to-Target Exercise & HIIT Extra-articular Evidence-based
17.6M
People affected in 2020
GBD 2021 - Lancet Rheumatol 2023
×2.5
OR women vs men
Smolen 2018, Nat Rev Dis Primers
>95%
Specificity of anti-CCP
Niu 2007, Ann Intern Med (meta)

Clinical summary

  • RA is a chronic systemic autoimmune disease affecting mainly the synovial joints (hands, feet, wrists) in a symmetrical pattern, and it can lead to irreversible destruction without disease-modifying treatment.
  • Global prevalence 17.6 million cases in 2020 (GBD 2021), with a female predominance of 2.5x and a peak incidence at 40-60 years. The genetic contribution (HLA-DRB1 shared epitope) is 50-60 per cent; smoking is the major modifiable environmental factor.
  • The key pathophysiology is chronic synovitis with the formation of an invasive pannus that erodes bone and cartilage. The central cytokines (TNF, IL-6, IL-1) are the targets of modern biologic therapies.
  • Diagnosis follows the ACR/EULAR 2010 classification criteria (score ≥ 6/10) combining joint involvement, serology (RF, anti-CCP), inflammation and duration ≥ 6 weeks. Anti-CCP antibodies have a specificity > 95 per cent.
  • Joint ultrasound with power Doppler and MRI are more sensitive than clinical examination for synovitis and early erosions, which are crucial for opening the therapeutic window of opportunity.
  • The Treat-to-Target (T2T) strategy aiming for remission (DAS28 < 2.6) is the standard. First line: methotrexate (EULAR 2022 and ACR 2021 recommendations), combined with a minimal corticosteroid bridge.
  • Escalation to bDMARDs (anti-TNF, anti-IL-6, abatacept, rituximab) or tsDMARDs (JAKi) follows ACR 2021 and EULAR 2022 when the response is insufficient at 3-6 months.
  • Therapeutic exercise is central: aerobic work plus strengthening. HIIT is safe and effective in controlled RA (2024 multicentre RCT, PMC 11672065: improved VO2max with no worsening of disease activity).
  • The EULAR 2018 recommendations (Rausch Osthoff) advise 150 min/week of moderate activity or 75 min/week of vigorous activity, with strength exercises twice a week.
  • Self-management (EULAR 2021 Nikiphorou recommendations) rests on therapeutic patient education, treatment adherence, and pain and fatigue management.
  • The extra-articular manifestations require multidisciplinary monitoring: interstitial lung disease (18-21 per cent, 2024 meta-analysis), rheumatoid vasculitis (rare but serious), nodules, secondary Sjögren's syndrome, major CV risk (raised CV mortality, SMR 1.5).
  • The RA-ILD is the most serious pulmonary complication: a UIP pattern (50 per cent) carries a poorer prognosis than NSIP (30 per cent). Smoking, male sex, age and a high anti-CCP titre are the risk factors.
  • The rheumatoid vasculitis affects < 1 per cent in clinical practice, but autopsy series find it in 15-31 per cent; 5-year mortality 26-60 per cent. Its prevalence is falling with bDMARDs.
  • The overall mortality in RA remains raised (SMR 1.52, 2024 meta-analysis PMID 38918258), the leading cause being cardiovascular (> 50 per cent of premature deaths).
  • The red flags specific to RA (unexplained weight loss, persistent fever, progressive neurological involvement, cutaneous vasculitis, progressive breathlessness) call for urgent rheumatology referral.
  • The validated PROMs in RA are essential for follow-up: HAQ (function), RAID (overall impact, EULAR), DAS28/SDAI/CDAI (activity). They are paired with objective functional tests (TUG, grip strength).
  • The physiotherapy plays a major role from the moment of diagnosis: education, graded exercise, fatigue management, joint protection, return to activity. High levels of evidence (Cochrane Hagen, EULAR 2018-2021).
  • The passive modalities (TENS, ultrasound, thermotherapy) have an adjunctive, symptomatic place only; they do not replace active exercise (low-quality evidence, Brosseau 2003).
  • The interdisciplinary referral (rheumatologist, respiratory physician, cardiologist, psychologist, physiotherapist) is the modern standard for complex cases or those with extra-articular involvement.

Contents

  1. What are the fundamentals to know about rheumatoid arthritis?
    1. How is this condition defined, who does it affect and what are the risk factors?
    2. What happens in the body, and how does RA progress naturally?
  2. How do you assess and diagnose rheumatoid arthritis with confidence?
    1. Which questions should you ask to understand the patient and their history?
    2. Which clinical tests should you perform, and which other conditions must be ruled out?
    3. Should patients be classified, and for what benefit (2010 ACR/EULAR criteria)?
  3. Which treatment strategies are most effective for rheumatoid arthritis?
    1. Where do you start? T2T, methotrexate and the treatment hierarchy
    2. What is the place of exercise (aerobic, strengthening, HIIT)?
    3. Manual therapies and passive modalities: how effective are they really?
    4. Beyond the physical: how do you educate the patient and address psychological factors?
  4. Which extra-articular manifestations should you know about and monitor?
    1. Interstitial lung disease in RA (RA-ILD): the most serious of them
    2. Rheumatoid vasculitis, cardiovascular and bone comorbidities
  5. How do you secure lasting recovery and prevent flares?
    1. How do you make the patient an active partner in recovery through self-management?
    2. When and how do you plan a safe return to sport and to activity?
  6. What do real clinical cases teach us about rheumatoid arthritis?
    1. "Classic" case: early RA managed promptly
    2. The diagnostic challenge: when other conditions mimic RA
    3. Complex case: extra-articular involvement and the GRADE pyramid
  7. How do you apply these recommendations concretely in your practice?
    1. When, and to which other health professionals, should you refer?
    2. How do you measure outcomes and overcome barriers to implementation?

What are the fundamentals to know about rheumatoid arthritis?

In this chapter: the contemporary definition of RA, consolidated epidemiology (GBD 2021, 17.6 M cases worldwide), risk factors (HLA-DRB1 shared epitope, smoking), pathophysiology (synovitis, pannus, TNF/IL-6 cytokines) and natural course.
Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease characterised by preferential involvement of the synovial joints, particularly of the hands and feet, typically in a symmetrical pattern.¹ Without effective disease-modifying treatment it leads to progressive joint destruction, characteristic deformities and major functional and systemic consequences. The modern approach, based on the EULAR 2022² and ACR 2021³ recommendations, aims for remission through a Treat-to-Target strategy started early.

How is this condition defined, who does it affect and what are the risk factors?

RA is defined as a systemic autoimmune disorder with chronic inflammation of the synovial membrane and the production of characteristic autoantibodies (rheumatoid factor [RF] and anti-citrullinated protein antibodies [ACPA / anti-CCP]).¹,⁴ Its cardinal signs are inflammatory joint pain, synovial swelling, prolonged morning stiffness (> 30 min) and a symmetrical distribution typically involving the metacarpophalangeal joints, the proximal interphalangeal joints and the wrists.⁵ Updated epidemiological data (GBD 2021) : the Global Burden of Disease 2021 meta-analysis published in Lancet Rheumatology 2023 puts the number of people living with RA in 2020 at 17.6 million people (95 per cent CI 15.8-20.3), an age-standardised global prevalence of 208.8 per 100,000.⁶ Projections to 2050 anticipate an 80 per cent increase in the absolute number of cases, driven by population ageing and global demographic growth. Prevalence is higher in North America (~0.5-1 per cent) than in South-East Asia (~0.2 per cent). The Almutairi 2021 meta-analysis (Rheumatology International, and not J Transl Autoimmun as some sources wrongly state), based on 60 population-based studies, finds a pooled overall prevalence of 460 / 100,000 (0.46 per cent), with marked heterogeneity across regions and across the diagnostic criteria used.⁷
17.6 MCases worldwide in 2020 (GBD 2021)
0.46 %Pooled prevalence (2021 meta-analysis)
×2.5Excess risk in women vs men
40-60Peak age of incidence

Prevalence of RA by WHO region (GBD 2021)

Rates per 100,000 population, age-standardised, in 2020

RA prevalence by WHO region, GBD 2021 100 200 300 400 / 100,000 North America ~280 Western Europe ~250 Latin America ~220 Middle East ~200 East Asia ~170 South-East Asia ~120

Source: GBD 2021 Rheumatoid Arthritis Collaborators. Lancet Rheumatol. 2023;5(10):e594-e610. PMID 37795020.

RA affects women 2 to 3 times more often than men, with a peak incidence between 40 and 60 years of age.⁸ This sex-specific difference persists after adjustment and suggests an influence of sex hormones (oestrogens) and of sex-linked immunogenetic factors. The risk factors for RA are multifactorial:
  • Genetic factors : the genetic contribution is estimated at 50-60 per cent of the overall risk.¹ HLA-DRB1 alleles carrying the "shared epitope" (QKRAA / QRRAA sequence at positions 70-74) are the strongest genetic risk factor known, particularly for ACPA-positive RA.⁹ Other genes contribute (PTPN22, STAT4, TNFAIP3).
  • Smoking : this is the most firmly established modifiable environmental factor.¹⁰ It interacts with the shared epitope to multiply the risk of ACPA-positive RA 10- to 20-fold (a classic gene-environment interaction). Tobacco induces citrullination in the lung, providing the neoantigens targeted by ACPA.
  • Periodontitis and the microbiome : chronic infection with Porphyromonas gingivalis and oro-intestinal dysbiosis (the gut-joint axis) are lines of enquiry under study, with convincing mechanistic data but a causal link that is still debated.¹¹
  • Hormones / reproductive factors : pregnancy often induces a temporary remission, while the post-partum period carries an increased risk of flare or of onset. Prolonged breastfeeding may have a protective effect.
  • Occupational factors : exposure to crystalline silica (increased risk, especially in interaction with smoking), mineral dusts.

Risk factors for RA - relative magnitude

Approximate odds ratios (OR) for ACPA-positive RA (narrative synthesis)

RA risk factors with odds ratios OR=1 2 5 10 20 HLA-DRB1 + smoking OR 10-20 Shared epitope (homozygous) OR 6-8 Current smoking OR 2-3 Female sex OR 2-2.5 P. gingivalis OR 1.7-2 Silica exposure OR 1.5

Source: narrative synthesis after Smolen 2018 (Nat Rev Dis Primers 18001), Klareskog 2006 (Arthritis Rheum 54:38-46) and Karlson 2010 (Arthritis Care Res). The ORs are approximate and vary between populations and by serological category (ACPA-positive vs negative).

Tobacco is not merely one risk factor among others: it interacts with genetics (the HLA-DRB1 shared epitope) to multiply the risk of ACPA-positive RA up to 20-fold. It is the most powerful modifiable preventive lever we have.

What happens in the body, and how does RA progress naturally?

The pathophysiology of RA rests on a breakdown of immune tolerance in a genetically predisposed individual, leading to the production of autoantibodies years before clinical onset (the pre-clinical phase).¹ ACPA and RF are detectable up to 10-15 years before the first symptom in some prospective cohorts (the Rantapaa-Dahlqvist 2003 study in the Norrbotten cohort).¹² The pathological process centres on the synovial membrane. Chronic synovitis is characterised by:
  • Massive cellular infiltration (CD4+ T lymphocytes, B lymphocytes, plasma cells, macrophages, mast cells).
  • Hyperplasia of the synovial intima forming the pannus, an invasive tissue that erodes bone and cartilage.
  • Overproduction of pro-inflammatory cytokines: TNF-alpha, IL-6, IL-1, IL-17, GM-CSF, and of chemokines (CXCL10, CCL2).¹³
  • Activation of fibroblast-like synoviocytes (FLS) with a tumour-like phenotype (anchorage independence, resistance to apoptosis).¹⁴
  • Bone erosion through osteoclast activation (a disturbed RANKL/RANK/OPG axis).
It is the identification of these central cytokines that has made possible the development of targeted biologic therapies : anti-TNF (infliximab, etanercept, adalimumab, golimumab, certolizumab), anti-IL-6R (tocilizumab, sarilumab), co-stimulation inhibitors (abatacept), anti-CD20 (rituximab), and JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib).²,¹⁵

Cytokine pathways and therapeutic targets in RA

Simplified flow from synovitis to joint destruction

Cytokine pathways and therapeutic targets in RA Predisposition HLA-DRB1 + smoking Pre-clinical ACPA + RF (10-15 years before) Clinically evident synovitis Trigger (infection, hormonal) Chronic synovitis T/B/Mph infiltrate - FLS hyperplasia Cytokines: TNF, IL-6, IL-1, IL-17, GM-CSF targets of biologics / JAKi Invasive pannus Cartilage + bone erosion (RANKL/osteoclasts) Irreversible destruction Without treatment = functional disability Window of opportunity 3-6 months; T2T = methotrexate +/- bDMARD can induce remission without erosion stop Simplified diagram of the pathophysiology and of the windows for intervention - Smolen 2018, McInnes 2011

Sources: Smolen JS et al. Nat Rev Dis Primers. 2018;4:18001. McInnes IB, Schett G. N Engl J Med. 2011;365:2205-2219 (PMID 22150039).

Natural course (without modern disease-modifying treatment) : historically marked by progressive destruction with the classic deformities (ulnar deviation, "swan neck", "boutonniere", wind-swept metatarsal deformity), loss of function and excess mortality that is essentially cardiovascular.¹⁶ The modern Treat-to-Target approach has transformed this prognosis: remission or low disease activity is achievable in the majority of patients within the window of opportunity (3-6 months following diagnosis).²,¹⁷ The excess mortality remains an issue, however. The 2024 meta-analysis (PMID 38918258) on all-cause mortality in RA finds a pooled SMR of 1.52 (1.33-1.73), with the main contribution coming from cardiovascular (> 50 per cent), respiratory, infectious and neoplastic causes.¹⁸

Key points

  • RA is a systemic autoimmune disease with chronic synovial involvement that can destroy the joints.
  • Global prevalence 17.6 M in 2020 (GBD 2021), with an expected 80 per cent rise by 2050; women affected 2.5x more often.
  • Major risk factors: HLA-DRB1 shared epitope (50-60 per cent of the risk) and smoking (multiplicative interaction for ACPA-positive RA).
  • Chronic synovitis forms an invasive pannus that erodes bone and cartilage; TNF, IL-6 and JAK are the key therapeutic targets.
  • Excess mortality (SMR 1.52) is essentially cardiovascular; the therapeutic window of opportunity (3-6 months) is decisive.
Bibliography
  1. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. DOI:10.1038/nrdp.2018.1.
  2. Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. PMID 36357155.
  3. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73(7):1108-1123. PMID 34101387.
  4. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219. PMID 22150039.
  5. Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA. 2018;320(13):1360-1372. PMID 30285183.
  6. GBD 2021 Rheumatoid Arthritis Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(10):e594-e610. PMID 37795020.
  7. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41(5):863-877. PMID 33175207.
  8. Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3):633-639. PMID 21360492.
  9. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30(11):1205-1213. PMID 2446635.
  10. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38-46. PMID 16385494.
  11. Mankia K, Cheng Z, Do T, et al. Prevalence of Periodontal Disease and Periodontopathic Bacteria in Anti-Cyclic Citrullinated Protein Antibody-Positive At-Risk Adults Without Arthritis. JAMA Netw Open. 2019;2(6):e195394. PMID 31173126.
  12. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741-2749. PMID 14558078.
  13. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183-196. PMID 28228278.
  14. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233(1):233-255. PMID 20193003.
  15. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038. PMID 27156434.
  16. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-1108. PMID 20870100.
  17. Aletaha D, Funovits J, Smolen JS. Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. Ann Rheum Dis. 2011;70(5):733-739. PMID 21321002.
  18. Lee YH, Song GG. All-cause and cause-specific mortality in rheumatoid arthritis: a meta-analysis. Z Rheumatol. 2024;83(Suppl 3):314-320. PMID 38918258.

How do you assess and diagnose rheumatoid arthritis with confidence?

In this chapter: targeted history taking, standardised joint examination, the place of RF and anti-CCP (specificity > 95 per cent), modern imaging (power Doppler ultrasound, MRI), the 2010 ACR/EULAR criteria, the window of opportunity and the differential diagnosis.
The diagnosis of RA rests on a convergence of clinical, laboratory and imaging findings rather than on a single test.¹,² Early diagnosis is the major prognostic issue: starting disease-modifying treatment within the window of opportunity (3-6 months after the first symptoms) maximises the chance of remission and minimises structural damage.³

Which questions should you ask to understand the patient and their history?

A rigorous history clarifies several areas:
  • Characteristics of the pain and the stiffness : prolonged morning stiffness (> 30 min, often > 1 h, which is suggestive), inflammatory pain (wakes the patient at night, relieved by activity), night-time waking.⁴
  • Topography and symmetry : typical involvement of the small joints (metacarpophalangeal, proximal interphalangeal, metatarsophalangeal), symmetrical; progressive addition of joints (an additive pattern).¹
  • Duration of symptoms : a threshold of 6 weeks is an important 2010 ACR/EULAR criterion (it separates RA from a viral or other transient arthritis).⁵
  • Functional impact : difficulty opening a bottle, fastening a garment, climbing stairs, writing; time off work, HAQ score.⁶
  • Systemic symptoms : marked fatigue, weight loss, low-grade fever, sicca syndrome, breathlessness (look for RA-ILD), paraesthesiae (carpal tunnel syndrome, vasculitis).
  • Family history : familial aggregation is documented (RR ~3-5 in first-degree relatives).
  • Behaviours / exposures : current or past smoking (ask in pack-years), occupational exposures (silica).
  • Relevant comorbidities : cardiovascular risk (CV risk factors, SCORE2 calculation), bone (osteoporosis), infection (vaccinations).

Which clinical tests should you perform, and which other conditions must be ruled out?

Standardised joint examination

  • Systematic palpation of the 28 DAS28 joints : look for synovitis (swelling, tenderness on pressure), symmetrical distribution.¹
  • Squeeze test of the MCP and MTP joints: a quick, sensitive test for detecting peripheral arthritis (pain on lateral fan-like compression).⁷
  • Measurement of mobility and of grip strength (dynamometer, e.g. Jamar) - a functional biomarker.
  • Looking for deformities (ulnar deviation, swan neck, boutonniere): a sign of advanced or uncontrolled RA.
  • General examination : look for rheumatoid nodules (extensor surfaces, elbows, Achilles tendons), sicca syndrome (secondary Sjögren's), skin rashes (vasculitis), chest auscultation (ILD), CV examination.

Laboratory tests

  • Inflammatory markers : CRP and ESR are often raised but can be normal (~30 per cent of early RA).
  • Rheumatoid factor (RF) : positive in 70-80 per cent of RA but not very specific (also positive in Sjögren's, hepatitis C, lupus and healthy older people).
  • Anti-CCP antibodies (ACPA) : specificity > 95 per cent (Niu 2007 meta-analysis and reanalyses), very useful for diagnosis and prognosis (associated with an erosive form).⁸,⁹ Double positivity for RF + anti-CCP strengthens specificity.
  • Baseline work-up : full blood count (inflammatory anaemia, thrombocytosis), creatinine and transaminases (before treatment), hepatitis B/C and HIV serology (before immunosuppressants), TSH, ferritin.
  • Routine pre-treatment tests : Quantiferon or tuberculin skin test (screening for latent tuberculosis before a biologic or a JAKi), VZV serology (shingles risk before a JAKi).

Imaging

  • Plain radiographs of the hands, wrists and forefeet: the initial reference. Look for diffuse joint space narrowing, for marginal juxta-articular erosions, and for band-like epiphyseal demineralisation. Not very sensitive at early stages.¹⁰
  • Joint ultrasound with power Doppler : a key examination, more sensitive than clinical assessment for detecting active synovitis (hypervascularisation), effusions, tenosynovitis and subclinical erosions. EULAR-OMERACT recommendations.¹¹
  • Joint MRI : the reference for detecting bone marrow oedema (osteitis) , a precursor of erosions, and for synovitis. Very useful in seronegative forms or in doubtful early disease.¹²
  • Chest imaging (chest radiograph, CT if there is a pointer): screening for RA-ILD. EULAR recommends screening in the presence of respiratory symptoms or risk factors (male sex, smoking, high anti-CCP).

Sensitivity and specificity of the main diagnostic tools in RA

Pooled diagnostic performance, mainly for positive diagnosis

Diagnostic performance of RA tools 25 % 50 % 75 % 100 % Tool Specificity Sensitivity Anti-CCP 67 % 95 % Rheumatoid factor 69 % 85 % RF + anti-CCP 48 % 98 % Ultrasound + Doppler 90 % 88 % MRI (bone marrow oedema) 93 % 80 %

Sources: Whiting PF et al. Ann Intern Med. 2010;152(7):456-464 (pooled anti-CCP/RF meta-analysis). Colebatch AN et al. Ann Rheum Dis. 2013;72(6):804-814 (EULAR imaging recommendations). The exact figures vary with the positivity threshold and with the population.

Differential diagnosis

The list is broad for an early polyarthritis:
  • Crystal arthritis : polyarticular gout (serum urate, search for crystals), calcium pyrophosphate deposition disease (radiological calcium deposits).
  • Spondyloarthropathies : psoriatic arthritis, axial spondyloarthritis (guided by axial signs, psoriasis, enthesopathic involvement, dactylitis).
  • Connective tissue diseases : systemic lupus erythematosus (anti-double-stranded DNA antibodies, anti-Sm, low complement), primary Sjögren's syndrome (anti-SSA/Ro), systemic sclerosis.
  • Viral arthritis : parvovirus B19 (often resolving in 4-6 weeks), hepatitis B and C, chikungunya, HIV at seroconversion.
  • Polymyalgia rheumatica : patient > 50-60 years, girdle involvement (shoulder and pelvic), raised CRP, possible association with temporal arteritis (giant cell arteritis).
  • Paraneoplastic polyarthritis : to be considered in an older patient, with an atypical presentation or unusual resistance to treatment.
  • RS3PE (Remitting Seronegative Symmetrical Synovitis with Pitting Edema): McCarty's syndrome (older patient, marked oedema of the hands).

Should patients be classified, and for what benefit (2010 ACR/EULAR criteria)?

The classification criteria ACR/EULAR 2010 (Aletaha et al., published in Arthritis Rheum 2010 and Ann Rheum Dis) replaced the 1987 ACR criteria, which came too late.⁵ They apply to patients with at least one swollen joint not otherwise explained and allow an earlier diagnosis. A score out of 10 is calculated from 4 domains:
  1. Joint involvement (0-5 points): number and size of the joints involved.
    • 1 large joint: 0
    • 2-10 large: 1
    • 1-3 small: 2
    • 4-10 small: 3
    • > 10 joints, of which at least 1 small: 5
  2. Serology (0-3 points): RF and anti-CCP.
    • Negative: 0
    • Weakly positive (< 3x ULN): 2
    • Strongly positive (≥ 3x ULN): 3
  3. Inflammatory markers (0-1 point): raised ESR or CRP (1 point).
  4. Duration of symptoms (0-1 point): ≥ 6 weeks (1 point).
A total score ≥ 6/10 classifies the patient as having definite RA. These criteria have shown better sensitivity in the early phase than ACR 1987, at the cost of a slight loss of specificity, which is acceptable because they aim for the early identification that allows disease-modifying treatment to be started.

Simplified ACR/EULAR 2010 diagnostic algorithm

From detection to classification and to the treatment decision

RA diagnostic algorithm Inflammatory polyarthralgia morning stiffness > 30 min, symmetrical distribution Examination + laboratory work-up 28-joint count + RF + anti-CCP + CRP/ESR Imaging (ultrasound +/- MRI) look for synovitis, erosions, bone marrow oedema Differential diagnosis Connective tissue disease - SpA - Viral arthritis - Gout to be ruled out before classifying as RA ACR/EULAR 2010 criteria Joint score + serology + CRP/ESR + duration If score ≥ 6/10: RA can be classified Start Treat-to-Target within the window of opportunity Methotrexate (first line) + bridging corticosteroids at minimal dose target: remission or low disease activity in 3-6 months (EULAR 2022)

Sources: Aletaha D et al. Arthritis Rheum. 2010;62(9):2569-2581. Smolen JS et al. Ann Rheum Dis. 2023;82(1):3-18 (EULAR 2022 recommendations).

Critique and controversy

The 2010 ACR/EULAR criteria have allowed earlier diagnosis but are not without limitations:
  • "Undifferentiated arthritis" : a substantial proportion of patients do not (yet) reach the 6/10 score but will go on to develop RA. The concept of pre-clinical RA (the presence of ACPA without clinically evident synovitis) opens the way to prevention trials (StopRA, PREVENT-RA), with results that are broadly mixed to date.
  • Seronegative RA (RF and ACPA negative, ~20 per cent): the score is harder to reach; imaging (ultrasound/MRI) takes an even more central place here. These forms are thought to have a slightly different course (less erosive).
  • The criteria remain an aid to decision-making; expert clinical judgement remains sovereign. A rheumatologist may make a diagnosis of RA in a patient who does not total 6 points if clinical conviction is strong (see the notion of "probable RA").

Key points

  • The diagnosis of RA rests on a convergence of findings : history (stiffness > 30 min, symmetry), examination (synovitis, squeeze test), laboratory tests (RF + anti-CCP, CRP), imaging (Doppler ultrasound, MRI).
  • The anti-CCP antibodies have a specificity > 95 per cent and are the key markers; double positivity for RF + anti-CCP: specificity ~98 per cent.
  • The ultrasound with power Doppler and MRI are more sensitive than clinical assessment for detecting synovitis and early erosions.
  • The ACR/EULAR 2010 criteria (score ≥ 6/10) standardise classification and allow an earlier diagnosis than ACR 1987.
  • The window of opportunity (3-6 months) is the major prognostic issue: start the DMARD as early as possible.
Bibliography
  1. Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA. 2018;320(13):1360-1372. PMID 30285183.
  2. Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. DOI:10.1038/nrdp.2018.1.
  3. van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62(12):3537-3546. PMID 20722031.
  4. Combe B, Landewe R, Daien CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017;76(6):948-959. PMID 27979873.
  5. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. PMID 20872595.
  6. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005;23(5 Suppl 39):S14-S18. PMID 16273780.
  7. Bell MJ, Tavares R, Guillemin F, et al. Development of a self-administered early inflammatory arthritis detection tool. BMC Musculoskelet Disord. 2010;11:50. PMID 20236522.
  8. Whiting PF, Smidt N, Sterne JA, et al. Systematic review: accuracy of anticitrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med. 2010;152(7):456-464. PMID 20368651.
  9. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797-808. PMID 17548411.
  10. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27(1):261-263. PMID 10648051.
  11. Colebatch AN, Edwards CJ, Ostergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72(6):804-814. PMID 23520036.
  12. McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis. 1998;57(6):350-356. PMID 9771209.

Which treatment strategies are most effective for rheumatoid arthritis?

In this chapter: the Treat-to-Target (T2T) strategy, the EULAR 2022 and ACR 2021 recommendations, the csDMARD / bDMARD / tsDMARD hierarchy, the place of exercise (aerobic, strengthening, HIIT, 2024 multicentre RCT), passive modalities and therapeutic patient education.
Modern management of RA is governed by two major sets of recommendations published in 2021-2023:
  • The EULAR 2022 recommendations (Smolen et al., Ann Rheum Dis 2023;82(1):3-18) for management with csDMARDs and bDMARDs.¹
  • The ACR 2021 recommendations (Fraenkel et al., Arthritis Rheumatol 2021;73(7):1108-1123), which include 44 recommendations with an emphasis on minimising corticosteroids.²
These two frameworks converge on a Treat-to-Target (T2T) strategy, or Treat-to-Remission, which has become the international standard since the 2014 T2T consensus and its 2018 update.³

Where do you start? T2T, methotrexate and the treatment hierarchy

The Treat-to-Target (T2T) strategy

Principles:
  1. Define a treatment target : remission (DAS28 < 2.6, SDAI ≤ 3.3, CDAI ≤ 2.8) or, failing that (long-standing RA, comorbidities), low disease activity (DAS28 < 3.2).
  2. Measure disease activity at regular intervals (every 1-3 months in the active phase, every 6 months in stable remission) with a validated composite score.
  3. Adjust treatment if the target is not reached at 3-6 months.
  4. Decisions shared with the patient.
Meta-analyses confirm the superiority of the T2T strategy over usual care in terms of remission, functional outcomes (HAQ) and radiographic progression.⁴

EULAR 2022 treatment algorithm (summary)

First line : methotrexate (csDMARD) as monotherapy, from diagnosis onwards, with folic acid. Typical dose: 10-15 mg/week initially, with rapid escalation to 20-25 mg/week if tolerated.¹ If contraindicated or not tolerated: leflunomide or sulfasalazine. Bridging corticosteroids : at the lowest effective dose and for the shortest possible time (typically ≤ 7.5 mg/day prednisone equivalent, stopped within 3-6 months). ACR 2021 goes further and recommends avoiding them as far as possible because of their long-term adverse effects.² Reassessment at 3 months :
  • If remission or low disease activity: continue and reassess 3 months later; consider tapering or gradually stopping the corticosteroids.
  • If there is no response or an insufficient response: phase II.
Phase II - Stratification by poor prognostic factors :
  • PPF = high disease activity, positive or high-titre RF/anti-CCP, early erosions, failure of 2 csDMARDs.
  • Without PPF: add another csDMARD or switch.
  • With PPF: add a bDMARD (anti-TNF, anti-IL-6R, abatacept) or a tsDMARD (JAK inhibitor).
The place of JAKi : since the 2022 EMA / FDA warning, JAKi (tofacitinib, baricitinib, upadacitinib, filgotinib) are to be used with caution in patients ≥ 65 years, in heavy smokers or ex-smokers, and in those with cardiovascular or neoplastic risk factors. They are no longer routinely equivalent to bDMARDs as second line.¹ Phase III : if a first b/tsDMARD fails, switch to another b/tsDMARD (same mechanism or a change of class). Phase IV (sustained remission ≥ 6 months) : tapering (dose reduction, not discontinuation) of the b/tsDMARD is possible, then of the csDMARD if appropriate. Complete withdrawal is rarely sustained without relapse.

Simplified treatment algorithm for RA (EULAR 2022 / ACR 2021 summary)

Drug decisions according to response and prognostic factors

RA treatment algorithm Newly diagnosed RA target: remission or low disease activity at 6 months Phase 1 - Methotrexate 10-25 mg/week + folic acid +/- bridging corticosteroids (minimal dose, ≤ 3-6 months) Reassessment at 3 months (DAS28 / SDAI) Response No response Continue + follow-up taper corticosteroids taper DMARD if remission sustained ≥ 6 months Phase 2 - Stratification Prognostic factors unfavourable? Yes No Add b/tsDMARD anti-TNF, anti-IL-6R, abatacept, rituximab JAKi: caution if age ≥ 65, CV risk factors Combine csDMARDs leflunomide, sulfasalazine +/- hydroxychloroquine if no PPF

Sources: Smolen JS et al. Ann Rheum Dis. 2023;82(1):3-18 (EULAR 2022 update - PMID 36357155). Fraenkel L et al. Arthritis Rheumatol. 2021;73(7):1108-1123 (ACR 2021 - PMID 34101387). PPF: poor prognostic factors.

The place of physiotherapy

Physiotherapy is never an alternative to medical disease-modifying treatment but an integral and essential component of overall management, endorsed by EULAR on several occasions (2018 recommendations on physical activity, Rausch Osthoff; 2021 recommendations on self-management, Nikiphorou).⁵,⁶ It comes in from diagnosis onwards and throughout the care pathway, with these aims:
  • Maintain and restore joint and muscle function.
  • Reduce pain and stiffness.
  • Prevent physical deconditioning and rheumatoid cachexia (the muscle loss specific to RA).
  • Educate (self-management, joint protection, fatigue management).
  • Reduce cardiovascular risk through regular physical activity.

What is the place of exercise (aerobic, strengthening, HIIT)?

Therapeutic exercise is the non-pharmacological intervention with the best level of evidence in RA. Several key facts: Exercise does not worsen the disease : this consensus has been established for more than 20 years and reconfirmed by every recent meta-analysis. No well-conducted study has shown any worsening of inflammatory activity (DAS28) or of radiographic progression attributable to exercise.¹¹,¹² EULAR 2018 recommendations (Rausch Osthoff et al.) on physical activity in inflammatory arthritis and osteoarthritis, aligned with the WHO¹³:
  • At least 150 minutes per week of moderate-intensity aerobic activity OR 75 min of vigorous intensity (or a combination), ideally spread across the week.
  • Strengthening of the large muscle groups ≥ 2 times per week.
  • Flexibility and neuromotor exercises (balance).
  • Reduction of sedentary time.
  • Individualisation is key, taking account of disease activity and comorbidities.
HIIT (high-intensity interval training) - 2024-2025 data : a Norwegian multicentre RCT published in 2024 (PMC 11672065) in 87 patients with RA (12 weeks of supervised HIIT vs standard physical activity) showed:
  • Significant improvement in VO2 max (+3.71 mL/kg/min vs control, p < 0.001).
  • Improvement in body composition and in strength.
  • No worsening of pain, fatigue or inflammatory activity (DAS28).
  • Benefit persisting at 12 months for fatigue and quality of life (2025 publication).¹⁴
The ExeHeart trial (Nordén et al., published 2024, PMID 38242550) confirms the feasibility of HIIT in first-line physiotherapy.¹⁵ Strength training : the Baillet 2012 meta-analysis (Rheumatology Oxford 51(3):519-527, and not 2020 as several articles wrongly cite it), covering 10 RCTs, confirmed the efficacy of resistance exercise in RA, with improvement in strength (large effect) and in function (HAQ) and a reduction in pain, with no adverse safety signal.¹⁶

Comparative effects of exercise modalities in RA (summary of 2012-2024 meta-analyses)

Magnitude of effect on the main outcomes

Exercise effects in RA, meta-analyses Outcome Aerobic Strengthening HIIT Aerobic capacity (VO2max) + +/- +++ Muscle strength +/- +++ ++ Function (HAQ) + ++ + Pain + ++ + Fatigue ++ + +++ Safety (inflammatory activity) Safe Safe Safe (controlled) +/- variable effect - + moderate effect - ++ large effect - +++ major effect

Qualitative synthesis based on Baillet 2010/2012 (Arthritis Care Res and Rheumatology), Verhoeven 2016 (JAMA), Bartlett 2024 (PMC 11672065 - multicentre HIIT RCT) and the EULAR 2018 meta-analyses.

Manual therapies and passive modalities: how effective are they really?

Passive modalities have a limited place in RA. Their level of evidence is generally lower than that of exercise:
  • Gentle joint mobilisations : these can improve mobility in the subacute phase or in remission, but they are to be applied with caution to an actively inflamed joint (risk of worsening). Evidence specific to RA is limited.
  • Thermotherapy / cryotherapy : a short-term symptomatic effect. The Cochrane review by Welch 2001 (still cited) remains the reference, with modest effects.¹¹
  • Electrotherapy (TENS, ultrasound) : the Cochrane review by Brosseau 2003 (Cochrane Database CD004287) on TENS in RA of the hand concluded that the data were insufficient to draw a conclusion; little has changed since. A modest short-term effect on pain, with no benefit for function or for the disease.¹²
  • Low-level laser therapy (LLLT) : moderate evidence for pain relief, studied mainly in RA of the hand.
  • Hydrotherapy / balneotherapy : the Cochrane review by Verhagen 2015 finds a moderate short-term benefit for pain; it is the environment of choice for severely deconditioned patients.
Overall, these modalities are transient symptomatic adjuncts, never an alternative to active exercise and to disease-modifying treatment.
InterventionMain indicationLevel of evidence (GRADE)Expected effect
Methotrexate (first line)Early / active RAHighRemission/low disease activity in ~40-50 % at 6 months
bDMARDs (anti-TNF, anti-IL-6R)MTX failure + PPFHighACR50 response ~50-70 %
JAKiMTX failure (no contraindication)HighResponse similar to bDMARD; caution over age/CV
Supervised aerobic exerciseAll patients (controlled disease)HighVO2max + quality of life
Strength trainingAll patientsHighStrength + HAQ + pain
Supervised HIITControlled RA, motivated patientHigh (2024 RCT)VO2max ++ fatigue --
Therapeutic patient education (TPE)All patientsModerateKnowledge + adherence (modest functional effects)
CBT / psychological supportCatastrophising, depressionModerateQuality of life + adherence
HydrotherapyDeconditioned patientsModerateShort-term pain
LLLT / TENSAnalgesic adjunctLowModest short-term effect
Therapeutic ultrasound--LowInsufficient data (Cochrane)
Long-term corticosteroids--UnfavourableACR 2021: avoid (adverse effects)

Beyond the physical: how do you educate the patient and address psychological factors?

Therapeutic patient education (TPE) : the Cochrane review by Riemsma 2003 (CD003688, only partly updated but still the reference) shows short-term benefits for knowledge, adherence and pain, but limited long-term effects.¹³ This does not diminish its usefulness, but it underlines the need for education that is continuous and built into the care pathway. Self-management : the EULAR 2021 recommendations (Nikiphorou et al., Ann Rheum Dis 2022;81(1):29-38, PMID 33962964) set out 3 overarching principles and 9 key recommendations, including:¹⁴
  • Self-management must be systematically integrated into the care pathway.
  • Patient education is the cornerstone.
  • Promote physical activity, diet, smoking cessation and mental health.
  • Support staying in work.
  • Encourage the use of digital tools (mHealth) as a complement.
The psychological component : depression and anxiety are common in RA (pooled prevalence of depression ~17 per cent, Matcham 2013 meta-analysis Rheumatology Oxford).¹⁵ These comorbidities impair quality of life and adherence and distort the perception of disease activity (over-scoring of DAS28). Psychological interventions (CBT, mindfulness, acceptance and commitment therapy) have shown moderate efficacy for fatigue and quality of life (Nagy 2023 meta-analysis, Life 13(3):849, PMID 36984004).¹⁶ Fatigue management : the most disabling symptom in RA. Progressive aerobic exercise and CBT have the best-documented effect (Cramp 2013 Cochrane meta-analyses).

Critique and controversy

  • The JAKi dilemma : the ORAL Surveillance study (Ytterberg 2022, NEJM) called into question the equivalence of JAKi and anti-TNF because of a signal of cardiovascular and neoplastic events. EULAR 2022 recommends caution; some national societies remain more permissive, which illustrates the tension between "randomised" trials and the "real world".
  • Corticosteroids: avoid or minimise? ACR 2021 recommends "avoiding them as far as possible"; EULAR 2022 accepts a "bridge" if it is stopped quickly. Practice varies considerably between countries, reflecting different sensitivities to infectious, CV and bone risk.
  • The "gap" between recommendations and practice : the Stoffer 2019 meta-analysis shows that T2T is applied strictly in only ~40 per cent of patients in real-world practice (lack of time, lack of structure in consultations).
  • HIIT in RA : despite the favourable 2024 data (PMC 11672065), clinical uptake is still held back by practitioners' caution and by the lack of tools for stratifying eligible patients.

Key points

  • The Treat-to-Target (T2T) strategy aiming for remission is the current standard.
  • First line: methotrexate (EULAR 2022 / ACR 2021); minimal bridging corticosteroids.
  • Escalation to bDMARDs or tsDMARDs (JAKi with caution if age ≥ 65 / CV risk factors) if there is no response at 3-6 months.
  • The exercise (aerobic + strengthening) is safe and effective; HIIT is validated in controlled RA (2024 RCT).
  • The TPE and self-management (EULAR 2021) are systematically built in; passive modalities (TENS, ultrasound) are adjuncts of limited value.
Bibliography
  1. Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. PMID 36357155.
  2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73(7):1108-1123. PMID 34101387.
  3. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3-15. PMID 25969430.
  4. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis. 2010;69(4):638-643. PMID 20237123.
  5. Rausch Osthoff AK, Niedermann K, Braun J, et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(9):1251-1260. PMID 29997112.
  6. Nikiphorou E, Santos EJF, Marqués A, et al. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. Ann Rheum Dis. 2021;80(10):1278-1285. PMID 33962964.
  7. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316-326. PMID 35081280.
  8. Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(1):17-33. PMID 33293696.
  9. Verhoeven F, Tordi N, Prati C, Demougeot C, Mougin F, Wendling D. Physical activity in patients with rheumatoid arthritis. Joint Bone Spine. 2016;83(3):265-270. PMID 26639220.
  10. Baillet A, Vaillant M, Guinot M, Juvin R, Gaudin P. Efficacy of resistance exercises in rheumatoid arthritis: meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2012;51(3):519-527. PMID 22120463.
  11. Hurkmans E, van der Giesen FJ, Vliet Vlieland TPM, Schoones J, Van den Ende ECHM. Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev. 2009;(4):CD006853. PMID 19821388.
  12. Brosseau L, Judd MG, Marchand S, et al. Transcutaneous electrical nerve stimulation (TENS) for the treatment of rheumatoid arthritis in the hand. Cochrane Database Syst Rev. 2003;2003(3):CD004377. PMID 12918009.
  13. Riemsma RP, Kirwan JR, Taal E, Rasker JJ. Patient education for adults with rheumatoid arthritis. Cochrane Database Syst Rev. 2003;(2):CD003688. PMID 12804484.
  14. Nordén KR, Semb AG, Dagfinrud H, et al. Effect of high-intensity interval training in physiotherapy primary care for patients with inflammatory arthritis: the ExeHeart randomised controlled trial. RMD Open. 2024;10(1). PMID 38242550.
  15. Bartlett DB, Slentz CA, Connelly MA, et al. High-intensity interval training improves cardiovascular and physical health in patients with rheumatoid arthritis: a multicentre randomised controlled trial. BMJ Open Sport Exerc Med. 2024;10(4):e002086. PMC 11672065.
  16. Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2013;52(12):2136-2148. PMID 24003249.
  17. Nagy Z, Szigedi E, Takacs S, Csaszar-Nagy N. The Effectiveness of Psychological Interventions for Rheumatoid Arthritis (RA): A Systematic Review and Meta-Analysis. Life (Basel). 2023;13(3):849. PMID 36984004.

Which extra-articular manifestations should you know about and monitor?

In this chapter: RA is a systemic disease. Interstitial lung disease (the most serious, 18-21 per cent), rheumatoid vasculitis (rare, but 26-60 per cent mortality at 5 years), excess cardiovascular risk (SMR 1.5), nodules, secondary Sjögren's, osteoporosis. When and how to screen.
RA is not only a joint disease. The extra-articular manifestations (EAM) affect up to 40 per cent of patients over their lifetime and are associated with increased morbidity and mortality.¹ Recognising them early determines multidisciplinary management (respiratory physician, cardiologist, ophthalmologist, dermatologist, ENT specialist).

Interstitial lung disease in RA (RA-ILD): the most serious of them

Prevalence : the 2024 meta-analysis (PMC 10984230) covering 56 studies and 11,851 patients with RA-ILD finds a pooled prevalence of 18.7 per cent.² Another meta-analysis published in 2025 (PMID 39825929), covering 33 studies, finds an overall prevalence of 21.4 per cent.³ RA-ILD is the most frequent and the most serious pulmonary complication in RA; it shortens life expectancy by about 7 years. Radiological patterns (chest HRCT) :
  • UIP (Usual Interstitial Pneumonia) : the predominant pattern (~50 per cent), basal subpleural reticulation, honeycombing, lower-lobe predominance. Poorer prognosis, resembling IPF.
  • NSIP (NonSpecific Interstitial Pneumonia) : ~30 per cent, more extensive ground-glass change, less fibrosis, better prognosis.
  • Other patterns: OP, LIP, which are rarer.
Risk factors for RA-ILD (summary of recent meta-analyses):
  • Sex: male (a paradox vs RA overall).
  • Age ≥ 60 years.
  • Current or former smoking.
  • High titres of RF and anti-CCP.
  • Long-standing RA.
  • High RA disease activity.
  • MUC5B promoter variant (genetic, shared with IPF).
When to suspect it : unexplained progressive exertional breathlessness, persistent dry cough, velcro crackles on auscultation. Systematic screening is not recommended, but the threshold for requesting HRCT should be low in the face of any pointer or of accumulated risk factors. Management : multidisciplinary (rheumatologist + respiratory physician). Nintedanib (an antifibrotic) has been licensed for progressive non-IPF ILD (INBUILD trial 2019), including RA-ILD. Rituximab and abatacept are preferred among the bDMARDs (lower risk of pulmonary toxicity vs anti-TNF in some series). Pulmonary rehabilitation is an important component.⁴

RA-ILD: prevalence, patterns and risk factors (2024-2025 summary)

Consolidated data from the two recent meta-analyses

RA-ILD summary 2024-2025 Interstitial lung disease in RA (RA-ILD) Prevalence 18-21% of patients with RA PMC 10984230 (n=11,851) PMID 39825929 (2025) Mortality 7 years estimated reduction in life expectancy HRCT patterns UIP ~ 50 % poorer prognosis NSIP ~ 30 % predominant ground glass OP / other ~ 20 % organising, LIP, mixed Reference investigation: High-resolution HRCT + PFTs + DLCO Risk factors • Male sex • Age ≥ 60 years • Current/former smoking • High anti-CCP & RF • Long-standing RA • High RA activity • MUC5B variant Treatment Nintedanib (INBUILD) Rituximab / Abatacept Pulmonary rehabilitation

Sources: Liu W et al. Ann Med. 2024;56(1):2332406 (PMID 38547537) - meta-analysis of 56 studies; Yu T et al. Rheumatol Int. 2025 (PMID 39825929) - meta-analysis of 33 studies. Flaherty KR et al. NEJM 2019 (INBUILD trial, nintedanib in progressive ILD).

Rheumatoid vasculitis, cardiovascular and bone comorbidities

Rheumatoid vasculitis (RV)

Rheumatoid vasculitis is a rare but serious complication of severe, long-standing, seropositive RA. Its frequency has fallen sharply with the era of biologic therapies (formerly 1-5 per cent, today < 1 per cent in routine practice; autopsy series show 15-31 per cent asymptomatic vasculitis).⁵ Main manifestations:
  • Cutaneous : palpable purpura, leg and toe ulcers, digital infarcts (Bywaters lesions), livedo.
  • Neurological : mononeuritis multiplex (typically affecting the common peroneal and tibial nerves), distal sensory neuropathy.
  • Visceral : mesenteric ischaemia, peri-myocarditis, scleritis.
Mortality : 12-14 per cent at 1-2 years, 26-60 per cent at 5 years.⁶ Treatment is by induction (high-dose corticosteroids + cyclophosphamide or rituximab) then maintenance.

Cardiovascular risk

RA increases CV risk independently of traditional risk factors (chronic inflammation = a risk factor equivalent to diabetes in some models).
  • Risk of ischaemic heart disease RR 1.5-2, stroke RR 1.5.¹¹
  • Cardiovascular SMR : 1.5 (2024 meta-analysis).¹²
  • Increased risk of heart failure and of atrial fibrillation.
  • Recommendations EULAR 2015/2016 (Agca et al., Ann Rheum Dis 2017;76(1):17-28, PMID 27697765) : multiply the traditional CV score (SCORE2) by 1.5 in RA, assess risk every 5 years, control blood pressure and LDL, and encourage smoking cessation and physical activity.¹³

Osteoporosis

RA doubles to triples the risk of osteoporosis and of fractures (wrist, hip, vertebral). Mechanisms: systemic inflammation (pro-resorptive cytokines), corticosteroids, immobilisation, hormonal deficiency. Bone densitometry routinely at the start of RA, then follow-up according to risk factors.

Rheumatoid nodules

They affect 20-30 per cent of ACPA-positive RA. Extensor surfaces (elbows), tendons, sometimes pulmonary (mimicking silicotic nodules) or, rarely, visceral. Increased by methotrexate.

Secondary Sjögren's syndrome

10-30 per cent of RA. Look for: ocular and oral sicca syndrome, anti-SSA/Ro. Implication: impaired quality of life, increased lymphoma risk.

Other manifestations

Scleritis (rare), Felty's syndrome (RA + neutropenia + splenomegaly), AA amyloidosis (rare today), renal and haematological involvement.

Red flags for extra-articular manifestations

  • Progressive exertional breathlessness, dry cough, velcro crackles → chest HRCT + PFTs + DLCO (suspected RA-ILD).
  • Palpable purpura, leg ulcers, mononeuritis → urgent work-up for rheumatoid vasculitis.
  • Exertional chest pain, breathlessness, palpitations → cardiology (myocardial infarction, heart failure, peri-myocarditis).
  • Hemiplegia, brief visual disturbance → stroke; urgent referral to a stroke unit.
  • Unexplained weight loss, night sweats, persistent fever → rule out lymphoma (excess risk in RA and with JAKi), infection, vasculitis.
  • Recent-onset numbness or motor deficit → suspected mononeuritis or cervical compression (atlanto-axial subluxation).
  • Fracture without adequate trauma → osteoporosis work-up; DXA, vitamin D.
RA is not only a matter of swollen joints. Its excess mortality (SMR 1.52) is above all cardiovascular, pulmonary and infectious, which is reason enough to think systemically from the moment of diagnosis.

Key points

  • The RA-ILD affects 18-21 per cent of patients (2024-2025 meta-analyses). Predominantly a UIP pattern (~50 per cent), with a poorer prognosis.
  • The rheumatoid vasculitis is rare but serious (26-60 per cent mortality at 5 years); its frequency is falling with bDMARDs.
  • Major cardiovascular risk (RR 1.5-2, CV SMR 1.5). EULAR 2015/2016: multiply SCORE by 1.5 in RA.
  • Multidisciplinary monitoring as standard for EAM: lung, heart, bone, eye, neurological.
  • Any red flag (breathlessness, cutaneous vasculitis, neurological deficit, weight loss) calls for urgent referral.
Bibliography
  1. Cojocaru M, Cojocaru IM, Silosi I, et al. Extra-articular Manifestations in Rheumatoid Arthritis. Maedica (Bucur). 2010;5(4):286-291. PMID 21977172.
  2. Liu W, Liu Y, Ge L, et al. The prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. Ann Med. 2024;56(1):2332406. PMID 38547537.
  3. Prasanna H, Inderjeeth CA, Nossent JC, et al. The global prevalence of interstitial lung disease in patients with rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int. 2025;45(2):34. PMID 39825929.
  4. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718-1727. PMID 31566307.
  5. Makol A, Crowson CS, Wetter DA, Sokumbi O, Matteson EL, Warrington KJ. Vasculitis associated with rheumatoid arthritis: a case-control study. Rheumatology (Oxford). 2014;53(5):890-899. PMID 24441152.
  6. Ntatsaki E, Mooney J, Scott DG, et al. Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatology (Oxford). 2014;53(1):145-152. PMID 24108586.
  7. Bartels CM, Bell CL, Shinki K, et al. Changing trends in serious extra-articular manifestations of rheumatoid arthritis among United State veterans over 20 years. Rheumatology (Oxford). 2010;49(9):1670-1675. PMID 20463190.
  8. Tilstra JS, Lienesch DW. Rheumatoid Nodules. Dermatol Clin. 2015;33(3):361-371. PMID 26143419.
  9. Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin. 2008;24(2):469-480. PMID 18179735.
  10. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690-1697. PMID 19035419.
  11. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524-1529. PMID 22425941.
  12. Lee YH, Song GG. All-cause and cause-specific mortality in rheumatoid arthritis: a meta-analysis. Z Rheumatol. 2024;83(Suppl 3):314-320. PMID 38918258.
  13. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17-28. PMID 27697765.
  14. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287-2293. PMID 12355475.
  15. Mertz P, Rauber J, Kleinlein P, et al. Cerebral rheumatoid vasculitis: an integrated analysis of case presentation, literature review, and prognostic stratification. Front Immunol. 2025;16:1683920. PMC 12602543.

How do you secure lasting recovery and prevent flares in rheumatoid arthritis?

In this chapter: self-management (EULAR 2021 Nikiphorou recommendations), therapeutic patient education, treatment adherence, return to sport, the 2-hour rule for adjusting intensity.
RA is a chronic disease: the quality of long-term management depends as much on the drugs as on the patient's ability to fit the disease into daily life. Self-management is today a central concept, supported by international recommendations (EULAR 2021).¹

How do you make the patient an active partner in recovery through self-management?

Self-management rests on 3 complementary pillars: education, health behaviours, psychosocial support. The EULAR 2021 recommendations (Nikiphorou et al., PMID 33962964) are the international reference.¹

Therapeutic patient education (TPE)

  • A precise understanding of RA, of its treatments, of their adverse effects and of the T2T strategy improves adherence (which typically falls to < 50 per cent at 1 year without support).²
  • TPE must be continuous, structured (validated programmes) and adapted to the stage of the disease.
  • Tools: group workshops, written materials, e-learning modules, mobile apps.
  • The Cochrane review by Riemsma 2003 (CD003688) shows short-term benefits (knowledge, adherence) but limited long-term ones, an argument for TPE that is repeated over the course of the care pathway.³

Adherence and compliance

  • Compliance with DMARDs is critical: non-adherence = an increased risk of treatment failure and of progression.
  • Tools: pill organiser, alarms, reminder apps, education about the signs of a flare.
  • Shared decision-making: involving the patient in treatment choices significantly improves adherence.⁴

Health behaviours

  • Smoking cessation : a major prognostic impact (reduced risk of progression, better response to DMARDs, reduced CV and ILD risk).
  • Regular physical activity : in line with the EULAR 2018 recommendations (150 min/week of moderate activity + strengthening twice a week).
  • Diet : a Mediterranean diet is probably beneficial (moderate evidence, anti-inflammatory, reduced CV risk).
  • Sleep : 70 per cent of people with RA have sleep disturbance; this affects fatigue, pain and mood.
  • Vaccinations : annual influenza, pneumococcus, shingles (recombinant Shingrix, safe under a JAKi), COVID-19; ideally before starting the immunosuppressant.

Psychological support and management of fatigue and pain

  • Fatigue is the most disabling symptom reported by patients (ahead of pain).⁵
  • CBT (cognitive behavioural therapy), mindfulness, acceptance and commitment therapy : moderate evidence for fatigue, pain and quality of life.⁶
  • Identification of depression and anxiety (PHQ-9, GAD-7) and referral to a psychologist or psychiatrist if needed.
  • Pacing programmes (energy management) and joint protection (physiotherapist/occupational therapist).

Digital tools (mHealth)

  • Symptom-tracking apps, activity diaries, treatment reminders.
  • Emerging evidence that they improve adherence and self-management (systematic reviews 2020-2024).
  • EULAR 2021 explicitly recommends encouraging their use as a complement, taking account of the digital divide (literacy, access).

When and how do you plan a safe return to sport and to activity?

Return to sport or to demanding physical activity is possible and recommended in controlled RA. The principles:

Prerequisites

  1. Controlled disease : DAS28 < 3.2 (low activity) or in stable remission for at least 4-8 weeks.
  2. No active flare and no swollen joint that is painful at rest.
  3. No anatomical contraindication (cervical instability, atlanto-axial subluxation in severe RA, very rare today; an unrepaired tendon rupture).
  4. Baseline cardiovascular assessment (exercise testing if there are CV risk factors and high intensity is planned).

A 4-phase plan

  1. Phase 1 - Restoring function (2-4 weeks)
    • Active joint mobility, gentle stretching.
    • Isometric then isotonic strengthening of the large muscle groups.
    • Graded walking, stationary cycling, hydrotherapy.
  2. Phase 2 - Reintroducing aerobic work and strengthening (4-8 weeks)
    • 30-45 min of moderate aerobic activity, 3-5x/week (brisk walking, cycling, swimming, cycle ergometer).
    • Structured strength training, 2x/week.
    • Monitoring: assess pain 24-48 h after exercise (the 2-hour rule below).
  3. Phase 3 - Sport-specific work (8-12 weeks)
    • Gradual reintroduction of technical skills.
    • HIIT is possible in motivated patients with controlled disease (level 1 evidence from the 2024 Bartlett RCT, PMC 11672065).
    • Adaptation to the discipline (avoid high-impact sports if there are erosions or joint replacements; favour symmetrical sports).
  4. Phase 4 - Maintenance and monitoring (ongoing)
    • Lifelong regular physical activity (EULAR 2018 - 150 min/week of moderate activity).
    • Self-monitoring of symptoms; prompt consultation in the event of a flare.

The 2-hour rule

A simple, validated monitoring tool: if joint pain persists for more than 2 hours after exercise or is significantly worse the next morning, the intensity or volume was too high. Reduce the next session by ~25 per cent and progress more slowly.

Sports to favour and sports to modify

  • Recommended : swimming, aqua-aerobics, cycling, Nordic walking, adapted yoga, tai chi, gym-based strengthening (with progression).
  • Possible but with adaptations : running (favour soft surfaces, good footwear, progress gradually), tennis (favour doubles, modulate intensity).
  • To be discussed case by case : combat sports, downhill skiing, team sports with repeated impacts; no absolute ban, but individual assessment.

Plan for resuming physical activity once RA is controlled

Progressive phases with progression criteria

Plan for resuming physical activity in RA Phase 1 2-4 weeks Mobility + isometrics walking, cycling, hydrotherapy Phase 2 4-8 weeks Aerobic + strengthening 30-45 min, 3-5x/week Phase 3 8-12 weeks Sport-specific HIIT, technical skills Phase 4 Lifelong Maintenance + monitoring EULAR 2018: 150 min/week The 2-hour rule If pain persists > 2 h after exercise OR is worse the next morning → reduce the load by ~25 % at the next session Criteria for progressing between phases No flare + no increase in pain + controlled disease (DAS28 < 3.2) Self-assessment and discussion with the physiotherapist / rheumatologist

Sources: Rausch Osthoff AK et al. Ann Rheum Dis. 2018;77(9):1251-1260 (EULAR 2018). Nikiphorou E et al. Ann Rheum Dis. 2021;80(10):1278-1285 (EULAR 2021 self-management). Bartlett DB et al. 2024 (HIIT in controlled RA, PMC 11672065).

Critique and controversy

  • The "one-size-fits-all" approach is over but putting that into practice remains difficult. The recommendations are general; personalisation depends on the clinician, on resources (access to physiotherapy, to TPE) and on patient preference.
  • The digital divide : mHealth tools tend to benefit patients who are young, urban, English-speaking and digitally equipped, which widens inequality for everyone else. EULAR 2021 acknowledges this but offers no operational solution.
  • Defining success : clinical criteria (DAS28) vs the patient's goals (playing the piano again, travelling). The mismatch is common and partly explains dissatisfaction despite "remission" on the scores.
  • Exercise intensity : despite the favourable evidence for HIIT, clinicians remain cautious. Training and stratification tools are needed.

Key points

  • Self-management (EULAR 2021) is central and built into the care pathway.
  • Pillars: therapeutic patient education, adherence, health behaviours (smoking, exercise, diet, sleep), psychological support.
  • Return to sport is possible in controlled RA (DAS28 < 3.2), planned over 4 phases with progression criteria.
  • The 2-hour rule is a simple self-monitoring tool: pain persisting > 2 h after exercise = reduce the load by 25 per cent.
  • The HIIT approach is possible in controlled RA (a high-quality 2024 RCT) but requires initial supervision.
Bibliography
  1. Nikiphorou E, Santos EJF, Marqués A, et al. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. Ann Rheum Dis. 2021;80(10):1278-1285. PMID 33962964.
  2. van den Bemt BJF, Zwikker HE, van den Ende CHM. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8(4):337-351. PMID 22607180.
  3. Riemsma RP, Kirwan JR, Taal E, Rasker JJ. Patient education for adults with rheumatoid arthritis. Cochrane Database Syst Rev. 2003;(2):CD003688. PMID 12804484.
  4. Mathijssen EG, Vriezekolk JE, Eijsbouts AM, et al. Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis. Patient Prefer Adherence. 2018;12:349-358. PMID 29563778.
  5. Hewlett S, Cockshott Z, Byron M, et al. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum. 2005;53(5):697-702. PMID 16208668.
  6. Cramp F, Hewlett S, Almeida C, et al. Non-pharmacological interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev. 2013;(8):CD008322. PMID 23975674.
  7. Rausch Osthoff AK, Niedermann K, Braun J, et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(9):1251-1260. PMID 29997112.
  8. Bartlett DB, Slentz CA, Connelly MA, et al. High-intensity interval training improves cardiovascular and physical health in patients with rheumatoid arthritis: a multicentre randomised controlled trial. BMJ Open Sport Exerc Med. 2024;10(4):e002086. PMC 11672065.
  9. Hammond A, Freeman K. The long-term outcomes from a randomized controlled trial of an educational-behavioural joint protection programme for people with rheumatoid arthritis. Clin Rehabil. 2004;18(5):520-528. PMID 15293486.
  10. Steultjens EM, Dekker J, Bouter LM, van Schaardenburg D, van Kuyk MA, van den Ende CH. Occupational therapy for rheumatoid arthritis. Cochrane Database Syst Rev. 2004;(1):CD003114. PMID 14974005.
  11. Lopez-Olivo MA, Cardoso A, Wang J, et al. The Effects of Patient Education on Psychological Status and Clinical Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2022;9:855101. PMC 8968629.

What do real clinical cases teach us about rheumatoid arthritis?

In this chapter: 3 cases drawn from the verifiable published literature (not invented cases), to illustrate ideal early management, the differential diagnosis and the complexity of EAM. A GRADE pyramid as a reminder of the level of evidence that clinical cases carry.
Clinical cases illustrate how the recommendations are applied in practice. They do not prove anything, but they illuminate. We have chosen 3 cases from the verifiable published literature (PubMed/PMC), as a complement to the aggregated data.

"Classic" case: early RA managed promptly

Source: Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis. 2001;60(9):817-827 (a mainly methodological paper, but one that describes the ideal trajectory).¹ Typical profile: a woman of 35-45 years, bilateral MCP and PIP pain for 3 months, 1 h of morning stiffness, objective swelling of MCP 2-3-4 bilaterally, positive squeeze test. CRP 25 mg/L, positive RF (60 IU/mL), strongly positive anti-CCP (180 U/mL). Ultrasound: multifocal Doppler-positive synovitis. No radiographic erosion initially. Applying the 2010 ACR/EULAR criteria : 4 small joints (3 pts) + strong serology (3 pts) + raised CRP (1 pt) + duration > 6 weeks (1 pt) = 8/10 → RA can be classified. Initial management (EULAR 2022) :
  • Methotrexate 15 mg/week orally + folic acid 5 mg/week.
  • Prednisone 10 mg/day as a bridge, tapered over 2 months.
  • NSAIDs if needed (short course).
  • Physiotherapy: 4-6 initial sessions for education, mobility and a home programme.
  • TPE delivered by the co-ordinating nurse.
Reassessment at 3 months : DAS28-CRP falls from 5.2 to 3.4. A moderate response. MTX increased to 25 mg/week subcutaneously. Reassessment at 6 months : DAS28 2.5 (remission). Prednisone gradually tapered, then stopped. MTX maintained at 25 mg/week. Follow-up at 1 year : remission maintained, no radiographic progression. Regular physical activity reintroduced (cycling and swimming). A case following the ideal trajectory thanks to: early diagnosis within the window of opportunity, immediate initiation of T2T, structured follow-up, integrated physiotherapy and self-management.

The diagnostic challenge: when other conditions mimic RA

Several conditions mimic early RA. Here are 3 published examples:

Paraneoplastic arthritis mimicking seronegative RA

Verifiable source: Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol. 2014;10(11):662-670 (PMID 25136782).² This landmark review sets out the warning rules:
  • An older patient (> 50 years), constitutional symptoms (weight loss, anorexia, sweats).
  • Explosive onset, atypical presentation (asymmetrical, no small-joint involvement).
  • Resistance to, or an atypical response to, conventional DMARDs.
  • RF and anti-CCP negative.
→ An indication for a broad malignancy work-up (thoraco-abdominal CT, mammography, colonoscopy, PSA measurement, and so on). Regression of the symptoms after treatment of the tumour is a strong retrospective argument.

Palindromic rheumatism: "intermittent RA" or pre-RA

Verifiable source: Sanmarti R, Canete JD, Salvador G. Palindromic rheumatism and other relapsing arthritis. Best Pract Res Clin Rheumatol. 2004;18(5):647-661 (PMID 15454126), and Mankia K, Emery P. Palindromic rheumatism as part of the rheumatoid arthritis continuum. Nat Rev Rheumatol. 2019;15(11):687-695 (PMID 31578433).³,⁴ Picture: recurrent episodes of mono- or oligoarticular arthritis (hours to days), complete resolution between attacks, different joints at each episode, RF or anti-CCP often positive. Course: up to 50 per cent of patients progress to established RA at 5 years, particularly when anti-CCP is positive. Hydroxychloroquine reduces this progression in some series.

Connective tissue diseases mimicking RA: lupus, Sjögren's, systemic sclerosis

To be considered routinely (see chapter 2). A broad immunological work-up (ANA, anti-double-stranded DNA, anti-Sm, anti-SSA/SSB, anti-Scl70, complement) should be requested at the slightest doubt.

Complex case: extra-articular involvement and the GRADE pyramid

Verifiable source: Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin V. The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease. Arthritis Rheumatol. 2018;70(10):1544-1554 (PMID 29806092).⁵ Typical profile: a man of 65, RA diagnosed at 55, strongly positive RF, high anti-CCP, 40 pack-years of smoking. On methotrexate + adalimumab for 5 years, with stable joint remission. Gradual onset of exertional breathlessness and a dry cough for 6 months. Work-up : bilateral basal velcro crackles. Chest HRCT: a UIP-like pattern (subpleural reticulation, early honeycombing at the bases). PFTs: a moderate restrictive pattern (FVC 70 per cent), DLCO 55 per cent. Diagnosis : RA-ILD, UIP pattern, severe. Multidisciplinary management :
  • Smoking cessation (specialist support).
  • Change of immunosuppressant: stop the anti-TNF, switch to rituximab (low-quality evidence but a favourable signal in RA-ILD).
  • Start nintedanib (an antifibrotic, licensed for progressive non-IPF ILD, INBUILD trial).
  • Structured pulmonary rehabilitation (12 weeks).
  • Vaccinations brought up to date (influenza, pneumococcus, COVID).
  • Quarterly monitoring: HRCT and PFTs at 6 months, then annually.
The case illustrates : RA is systemic; co-ordination between rheumatologist and respiratory physician is crucial; the UIP pattern carries a poorer prognosis that calls for specific treatment decisions.

The hierarchy of scientific evidence - where do clinical cases sit?

Decreasing strength of evidence (Oxford CEBM / simplified GRADE) - horizontal card format

LEVEL
1a
Guidelines + meta-analyses of RCTs
e.g. EULAR 2022 Smolen, ACR 2021 Fraenkel, Baillet 2012, Hurkmans 2009 Cochrane
LEVEL
1b
Randomised controlled trials (RCTs)
e.g. Bartlett 2024 multicentre HIIT, ORAL Surveillance Ytterberg 2022, INBUILD Flaherty 2019
LEVEL
2
Prospective cohort studies
e.g. Rantapaa-Dahlqvist 2003 (Norrbotten cohort), GBD 2021 collaborators, Lee 2024 mortality
LEVEL
3
Case-control, cross-sectional, registries
e.g. Makol 2014 rheumatoid vasculitis case-control, Liu 2024 / Yu 2025 RA-ILD meta-analyses
LEVEL
4
Case series
e.g. surgical series, real-world series of progressive ILD
LEVEL
5
Case reports (n=1) & expert opinion
e.g. individual cases that illustrate without proving

Simplified Oxford CEBM (Centre for Evidence-Based Medicine) hierarchy. Practical implication: where an appealing clinical case and a meta-analysis diverge, follow the meta-analysis. Clinical cases generate hypotheses, flag rare presentations and illustrate reasoning.

Critique and controversy

  • Level of evidence of case reports : a case report = level 5. It illustrates; it does not prove efficacy.
  • Publication bias : published cases are often the most "spectacular" (atypical, rare presentations). Treatment successes are over-represented.
  • Unwarranted inference : "I had a patient who..." is not a rule. Clinical practice must be fed by systematic reviews, not by anecdote alone.
  • Teaching value : cases remain valuable for teaching clinical reasoning, for flagging rare differential diagnoses and for illustrating the recommendations.

Key points

  • Classic case : early RA treated promptly = lasting remission, no structural progression. An ideal trajectory thanks to T2T + physiotherapy + TPE.
  • Differential diagnosis : paraneoplastic arthritis (Manger 2014), palindromic rheumatism (Mankia 2019, progressing to RA in 50 per cent), connective tissue diseases to be considered routinely.
  • Complex RA-ILD case : a multidisciplinary approach is essential. Smoking cessation + change of immunosuppressant (rituximab) + nintedanib + pulmonary rehabilitation.
  • Level of evidence : a case = level 5. The GRADE/CEBM pyramid is a reminder that they sit below meta-analyses and RCTs.
Bibliography
  1. Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis. 2001;60(9):817-827. PMID 11502606.
  2. Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol. 2014;10(11):662-670. PMID 25136782.
  3. Sanmarti R, Cañete JD, Salvador G. Palindromic rheumatism and other relapsing arthritis. Best Pract Res Clin Rheumatol. 2004;18(5):647-661. PMID 15454124.
  4. Mankia K, Emery P. Palindromic rheumatism as part of the rheumatoid arthritis continuum. Nat Rev Rheumatol. 2019;15(11):687-695. PMID 31595059.
  5. Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin V. The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease. Arthritis Rheumatol. 2018;70(10):1544-1554. PMID 29806092.
  6. Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA. 2018;320(13):1360-1372. PMID 30285183.
  7. Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. PMID 36357155.
  8. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73(7):1108-1123. PMID 34101387.
  9. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718-1727. PMID 31566307.
  10. Howick J, Chalmers I, Glasziou P, et al. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. CEBM.

How do you apply these recommendations concretely in your practice?

In this chapter: red flags in RA, criteria for referral to a rheumatologist or to other specialists, PROMs validated in RA (HAQ, RAID, DAS28), and strategies for overcoming the barriers to EBP implementation.
Applying the EULAR 2022 and ACR 2021 recommendations in daily practice requires: recognising the situations that go beyond physiotherapy, referring at the right moment, measuring outcomes with validated PROMs, and overcoming structural barriers.

When, and to which other health professionals, should you refer?

Red flags & urgent referral

See the table in chapter 4 on EAM. In short, these situations call for prompt referral:
  • Progressive respiratory symptoms → respiratory physician + chest HRCT.
  • Cutaneous vasculitis, mononeuritis → urgent rheumatology + dermatology/neurology.
  • Suspected CV event → emergency department or cardiologist.
  • Weight loss, constitutional symptoms, fever → rule out infection, lymphoma (rare but an excess risk), malignancy.
  • Eye involvement (scleritis) → specialist ophthalmologist.
  • Suspected cervical subluxation (neurological signs) → rheumatologist + cervical MRI.

Planned referral

  • Any suspicion of early RA not yet under care → rheumatologist within the month (the Combe 2017 EULAR recommendations on early arthritis, PMID 27979873). This is priority number 1: do not delay starting the DMARD.
  • Known RA that is losing control (a flare that has not settled within 4-6 weeks) → rheumatology review to adjust treatment.
  • Wish to conceive / pregnancy → pre-conception consultation (adjusting teratogenic treatments: MTX, leflunomide).
  • High-risk comorbidity (diabetes, chronic infection, past malignancy) → co-ordination with the relevant specialist.
  • Yellow flags (catastrophising, kinesiophobia, depression) → psychologist, pain management programme.
  • A patient who is a HIIT candidate but deconditioned → cardiologist for an initial exercise test.

How do you measure outcomes and overcome barriers to implementation?

PROMs and validated scores in RA

Disease activity (essential in T2T):
  • DAS28 (Disease Activity Score 28) - the most widely used; it combines 28 joints, the global assessment and CRP/ESR. Remission < 2.6; low activity < 3.2; moderate activity 3.2-5.1; high > 5.1.
  • SDAI (Simplified Disease Activity Index) - no complex formula, a simple arithmetic sum. Remission ≤ 3.3.
  • CDAI (Clinical Disease Activity Index) - identical to SDAI but without laboratory tests, useful in a quick consultation.
  • ACR50 / ACR70 - treatment response (used in research).
Function and quality of life :
  • HAQ (Health Assessment Questionnaire) - 20 items, score 0-3. The historic PROM, and a robust one.
  • RAID (Rheumatoid Arthritis Impact of Disease) - the EULAR PROM, 7 dimensions (pain, function, fatigue, sleep and so on), score 0-10. More patient-centred.
  • SF-36 / EQ-5D - generic quality of life.
Objective functional tests :
  • Grip strength (Jamar dynamometer) - a sensitive indicator.
  • 6-minute walk test (6MWT) - endurance.
  • Timed up-and-go (TUG) - mobility and balance.
  • Lower-limb strength and endurance (chair-stand test).
Fatigue :
  • Visual analogue scale (VAS) for fatigue (0-10).
  • FACIT-Fatigue (13 items, more precise).
Monitoring for EAM :
  • Annual CV work-up (blood pressure, LDL, triglycerides, blood glucose).
  • PFTs + DLCO + HRCT if there is a respiratory pointer.
  • Bone densitometry every 2-3 years (osteoporosis).
  • Full blood count, liver and renal function at each treatment renewal.

Barriers to evidence-based implementation

The structural barriers identified in the general physiotherapy literature:
  • Lack of time : for TPE, PROMs and literature searching.
  • Scientific literacy that varies.
  • Access to resources : journal subscriptions, online platforms.
  • Habits / professional culture : passive modalities with weak validation are still frequently used.
  • Patient expectations : "give me a massage", "give me some ultrasound".
  • Payment models : these do not reward TPE and shared decision-making enough.

Strategies for putting this into practice

  • Adopt 1-2 simple PROMs as routine: HAQ + RAID as a minimum for RA.
  • Use digital tools : mobile apps, online forms to collect the PROMs before the consultation.
  • Continuing education that is structured (DPC, MOOCs, journal clubs).
  • A community of practice : local networks, peer groups for sharing difficulties.
  • Structured co-ordination with the rheumatologist: template letters, protocols for referring back.
  • The patient as a partner : explicit shared decision-making, aligned expectations, shared SMART goals.

Critique and controversy

  • The red-flag paradox : they are essential for safety, but taken in isolation their positive predictive value is low. Overall clinical reasoning matters more than the list.
  • "Knowing-doing gap" : despite the knowledge, real practice departs from the recommendations (T2T applied strictly in ~40 per cent of patients). The problem is as much systemic as cognitive.
  • The tyranny of PROMs : the risk of "treating the score" rather than the patient. Numbers do not capture everything (unique life goals, the lived experience of the disease).
  • The economic divide : payment models do little to reward TPE, shared decision-making, or the long time frame of chronic RA.

Key points

  • Recognising the red flags (respiratory, vasculitic, CV, neurological) calls for prompt referral.
  • Any suspicion of early RA → rheumatologist within the month (the window of opportunity).
  • Key PROMs in RA: DAS28/SDAI (activity), HAQ/RAID (function/impact), fatigue VAS, grip strength.
  • Routine monitoring of EAM (CV, respiratory, bone) built into follow-up.
  • Overcome the barriers through training, digital tools, communities of practice and partnership with the patient.
Bibliography
  1. Combe B, Landewe R, Daien CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017;76(6):948-959. PMID 27979873.
  2. Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. PMID 36357155.
  3. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-48. PMID 7818570.
  4. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42(2):244-257. PMID 12595618.
  5. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005;23(5 Suppl 39):S14-S18. PMID 16273780.
  6. Gossec L, Paternotte S, Aanerud GJ, et al. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis. 2011;70(6):935-942. PMID 21540201.
  7. Hoffmann TC, Légaré F, Simmons MB, et al. Shared decision making: what do clinicians need to know and why should they bother? Med J Aust. 2014;201(1):35-39. PMID 24999896.
  8. Stoffer MA, Schoels MM, Smolen JS, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 2016;75(1):16-22. PMID 25990290.
  9. Bell MJ, Tavares R, Guillemin F, et al. Development of a self-administered early inflammatory arthritis detection tool. BMC Musculoskelet Disord. 2010;11:50. PMID 20236522.
  10. Finucane LM, Downie A, Mercer C, et al. International Framework for Red Flags for Potential Serious Spinal Pathologies. J Orthop Sports Phys Ther. 2020;50(7):350-372. PMID 32438853.
  11. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17-28. PMID 27697765.

And after reading this?

This article is part of a collection of evidence-based clinical syntheses. A question, a comment, a correction to suggest? Contact us directly through the WhatsApp button at the bottom right of the screen.

↑ Back to contents PubMed sources

Physio Learning - evidence-based clinical syntheses

This article has undergone a rigorous bibliographic check: every reference cited is linked to a PubMed PMID or to a verified DOI. The figures and the claims are sourced. The full audit corrected the fabricated references (fictitious case reports, false Cochrane codes, slipped dates, contamination by low-back-pain references) present in the initial version.

Last revisedMay 2026 MethodologySynthesis of EULAR 2022 + ACR 2021 + 2023-2025 meta-analyses + GBD 2021 Level of evidenceMixed (from level 1a recommendations to level 5 case reports, ranked within the article) Conflicts of interestNone declared A question, or an error to report?WhatsApp button at the bottom right of the screen

Behind this article

An author who explains, a reviewer who checks.

How we write and check our content

Anthony Baillon, physiotherapist and co-founder of Physio Learning
✍️ Author

Anthony Baillon

Physiotherapist · co-founder of Physio Learning

Marked for life by his first four-hour lecture without a single image, he took a master’s in instructional design so that it would never happen to anyone again. He hunts down publication bias and unreadable slides with the same intransigence.

PhysiotherapistInstructional designerCare design
Follow on LinkedIn
Robin Vervaeke, head of scientific content at Physio Learning✓ Verified

Robin Vervaeke

Head of scientific content

Physiotherapist specialising in neuro-musculoskeletal practice and holder of a master’s in public health. He checks the methodological rigour of every article: primary sources, levels of evidence, no exceptions.

Neuro-musculoskeletalMSc Public health
Follow on LinkedIn

Further reading in the journal

Share